Xencor | XNCR - Current Liabilities


Xencor reported $73.46M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
AbbVie USD 42.1B 1.19B Mar/2026
Alnylam Pharmaceuticals USD 1.35B 116.87M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Arrowhead Research USD 295.22M 52.2M Mar/2026
AstraZeneca USD 32.57B 1.95B Mar/2026
Biogen USD 3B 350.5M Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Karyopharm Therapeutics USD 92.06M 4.9M Dec/2025
MacroGenics USD 95.94M 52.82M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Xencor USD 73.46M 22.45M Mar/2026